Tag: livanova
LivaNova announces randomisation of 150th bipolar depression patient in RECOVER clinical...
LivaNova has announced that the 150th bipolar depression patient has been randomised in its RECOVER clinical study—a prospective, multicentre, double-blinded randomised controlled trial investigating...
LivaNova launches new vagus nerve stimulation therapy for drug-resistant epilepsy
LivaNova has launched SenTiva DUO—an implantable pulse generator (IPG) with a dual-pin header intended to provide vagus nerve stimulation (VNS) therapy for patients with...
First patient implanted in clinical study assessing hypoglossal nerve stimulation for...
LivaNova has announced the first patient has been implanted as part of an investigational device exemption (IDE) clinical study, dubbed OSPREY (Treating obstructive sleep apnea using...
New study shows significant positive impact of vagus nerve stimulation therapy...
Adding vagus nerve stimulation (VNS) therapy to treatment as usual has been demonstrated to improve outcomes in patients with treatment-resistant bipolar depression (TRBD). In...
RECOVER trial design evaluating vagus nerve stimulation for treatment-resistant depression published
LivaNova announces a publication in Contemporary Clinical Trials, which details the design for a prospective, multicentre, randomised controlled blinded trial demonstrating the safety and...
New study shows significant positive impact of vagus nerve stimulation therapy...
Adding vagus nerve stimulation (VNS) therapy to treatment as usual (TAU) has been demonstrated to improve outcomes in patients with treatment-resistant bipolar depression (TRBD)....
LivaNova collaborates with Verily to fuel research into vagus nerve stimulation...
LivaNova has announced a research collaboration with Verily, an Alphabet company, to capture measures of depression within its RECOVER clinical study, which is evaluating...
CMS trial clearance for LivaNova’s vagus nerve stimulation therapy for treatment-resistant...
LivaNova has recognised that the US Centers for Medicare & Medicaid Services (CMS) finalised its National Coverage Determination (NCD) for the LivaNova vagus nerve...
FDA approves SenTiva device for treatment of epilepsy
LivaNova has received US Food and Drug Administration (FDA) approvals for its latest Vagus Nerve Stimulation (VNS) Therapy System, which consists of the SenTiva implantable...
LivaNova’s VNS Therapy receives CE mark for expanded MRI labelling
LivaNova's latest VNS Therapy system has received CE mark for expanded MRI labelling. VNS Therapy is now the only implantable device indicated for epilepsy...
LivaNova’s VNS Therapy receives FDA approval for expanded MRI labelling
LivaNova’s latest vagus nerve stimulation (VNS Therapy) system has received US Food and Drug Administration (FDA) approval for expanded magnetic resonance imaging labelling.
According...
